In Vivo Cardiac Cellular Reprogramming Efficacy Is Enhanced by Angiogenic Preconditioning of the Infarcted Myocardium With Vascular Endothelial Growth Factor

Megumi Mathison, MD, PhD; Robert P. Gersch, PhD; Ahmed Nasser, MD; Sarit Lilo, PhD; Mallory Korman, BS; Mitchell Fourman, M.Phil; Neil Hackett, PhD; Kenneth Shroyer, MD, PhD; Jianchang Yang, MD, PhD; Yupo Ma, MD, PhD; Ronald G. Crystal, MD; Todd K. Rosengart, MD

Background—In situ cellular reprogramming offers the possibility of regenerating functional cardiomyocytes directly from scar fibroblasts, obviating the challenges of cell implantation. We hypothesized that pretreating scar with gene transfer of the angiogenic vascular endothelial growth factor (VEGF) would enhance the efficacy of this strategy.

Methods and Results—Gata4, Mef2c, and Tbx5 (GMT) administration via lentiviral transduction was demonstrated to transdifferentiate rat fibroblasts into (induced) cardiomyocytes in vitro by cardiomyocyte marker studies. Fisher 344 rats underwent coronary ligation and intramyocardial administration of an adenovirus encoding all 3 major isoforms of VEGF (AdVEGF-All6A) or an AdNull control vector (n=12/group). Lentivirus encoding GMT or a GFP control was administered to each animal 3 weeks later, followed by histologic and echocardiographic analyses. GMT administration reduced the extent of fibrosis by half compared with GFP controls (12±2% vs 24±3%, P<0.01) and reduced the number of myofibroblasts detected in the infarct zone by 4-fold. GMT-treated animals also demonstrated greater density of cardiomyocyte-specific marker beta myosin heavy chain 7+ cells compared with animals receiving GFP with or without VEGF (P<0.01). Ejection fraction was significantly improved after GMT vs GFP administration (12±3% vs −7±3%, P<0.01). Eight (73%) GFP animals but no GMT animals demonstrated decreased ejection fraction during this interval (P<0.01). Also, improvement in ejection fraction was 4-fold greater in GMT/VEGF vs GMT/null animals (17±2% vs 4±1%, P<0.05).

Conclusions—VEGF administration to infarcted myocardium enhances the efficacy of GMT-mediated cellular reprogramming in improving myocardial function and reducing the extent of myocardial fibrosis compared with the use of GMT or VEGF alone. (J Am Heart Assoc. 2012;1:e005652 doi: 10.1161/JAHA.112.005652)

Key Words: angiogenesis • gene therapy • myocardial infarction • stem cells

Coronary artery disease (CAD) remains the leading cause of death in the west, in part because of the still limited options for the treatment of diffuse CAD, myocardial infarction, and congestive heart failure.1–4 Cardiac stem cell therapy has been embraced as a new approach to treating end-stage heart disease that theoretically repopulates otherwise permanently scarred myocardium with contractile cells.5–13 The creation of induced pluripotent stem cells (iPSCs) and the generation of cardiomyocyte-like cells from iPSCs appear to have represented breakthroughs in this field,14–23 but recent reports of iPSC tumorigenesis and immunogenicity may ultimately reflect limits of the clinical applicability of iPSCs, as may the logistic challenges of iPSC delivery in the clinical setting.24–27

The recent discovery by Ieda et al, as confirmed by others, that a trio of “cardio-differentiating” transcription factors could be used to generate “induced cardiomyocyte” (iCM) cells directly from somatic cells offers the exciting new possibility of generating autologous cells that possess characteristics that are at least consistent with those of a cardiomyocyte phenotype production.28–35 Perhaps more important, this novel regenerative strategy offers the intriguing potential to bypass iPSC staging and convert myocardial scar fibroblasts into functional iCMs in situ, potentially transforming regions of myocardial infarction back into functioning myocardium.30,32–34

From the Departments of Surgery (M.M., R.G., A.N., S.L., M.K., M.F., J.Y., T.K.R.) and Pathology (M.K., K.S., J.Y., Y.M.), Stony Brook University Medical Center, Stony Brook, NY; Department of Genetic Medicine, Weill Cornell Medical College, New York, NY (N.H., R.C.).

Dr Rosengart is now located at Baylor College of Medicine.

Dr Mathison and Dr Gersch contributed equally to this work.

Correspondence to: Todd K. Rosengart, MD, Michael E. De Bakey Department of Surgery, Baylor College of Medicine, 1709 Dryden Rd, Suite 1500, Houston, TX 77030. E-mail: todd.rosengart@bcm.edu

Received October 8, 2012; accepted November 1, 2012.

© 2012 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell. This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
In the context of conflicting recent reports regarding the potential efficacy of such in situ myocardial regeneration,30,32–36 we hypothesized that ischemia could adversely affect the survival and/or function of iCMs in the infarct zone, much as it causes the loss of native cardiomyocytes and exogenous (stem cell) implants.37 In this scenario, adequate myocardial scar vascularization would be an important component of an optimized in situ cellular reprogramming strategy.40,41 We now accordingly report that the (lentivirus-mediated) administration of a cocktail of 3 transcription factors (Gata4, Mef2c, and Tbx5 [GMT]), used as a stimulus for iCM generation together with administration of an adenovirus encoding all 3 major isoforms of vascular endothelial growth factor (VEGF), results in greater improvements in postinfarct myocardial function than does the administration of GMT or VEGF alone.

Methods

Vectors and Cells

An adenovirus vector (AdVEGF-All6A+) based on an Ad5 serotype backbone with deletions in the E1 and E3 regions and containing an artificial splice sequence cassette was used to provide delivery of all 3 major isoforms of VEGF (121, 165, and 189).12 An analogous construct with an empty expression cassette (AdNull) was used as a control vector.

Lentivirus vectors were constructed to provide expression of GMT in targeted myocardial tissues. For GMT vector construction, RNA was first isolated from rat heart using TRIzol reagent (Invitrogen) and converted to cDNA using a reverse transcription kit (Roche). These samples (for Mef2c) were allowed to transdifferentiate under normal culture conditions over a 14-day course. These cells were washed twice with PBS and were then aspirated and pellets diluted in viral diluent (3% sucrose, 10 mmol/L Tris-HCl, pH 7.6, 150 mmol/L NaCl).

Dermal fibroblasts derived from 1-cm² biopsy samples of the abdominal skin of Fisher 344 rats were plated onto plastic dishes.18,28 Attached fibroblasts were cultured for 7 days in DMEM/10% FBS at 10⁴/cm². Cells were then replated and infected with appropriate vectors after 24 hours. Cardiomyocytes were obtained from the neonatal ventricles of Sprague Dawley rats (gift of E. Entcheva, Stony Brook University, Stony Brook, NY), which were cut into small pieces and digested with collagenase type II solution. A single-cell suspension of primary cardiomyocytes was then obtained by gentle passage through a 40-μm cell strainer, and cells were plated onto tissue culture–treated dishes (Thermo Fisher Scientific).

In Vitro Immunofluorescence Studies

Lentivirus encoding GMT or GFP control vectors in the presence of 8 μg/mL polybrene (Millipore) was added to rat dermal fibroblast culture media (DMEM+10% FBS) for 16 hours. This medium was then removed and the cells were allowed to transdifferentiate under normal culture conditions over a 14-day course. These cells were washed twice with PBS and fixed with 4% paraformaldehyde (Affymetrix) for 10 minutes. Cells were then permeabilized with 0.5% Saponin (Sigma) at room temperature for 10 minutes. Slides were blocked with 10% goat serum (Santa Cruz Technology) before incubation in 5% goat serum with primary

Table 1. Primers Used for Plasmid Construction

| Primer Name | Sequence | Melting Temperature |
|-------------|----------|---------------------|
| Gata4 5'    | GCCGGTGCACTATGACAAAGCCTGGCTATG | 72.6 |
| Gata4 3'    | GATCTCGAGTACGCCGGTATTGTGCCCATTG | 70.9 |
| Mef2c 5'    | GGACTGTCGACATGGGAGAAAAAGATCAG | 68.5 |
| Mef2c 3'    | TGGACTCGATGTCATTGCCATCTTCCAGAG | 71.7 |
| Tbx5 5'     | CACCGTGCAATGCCCCGCGGAATGAG | 73.4 |
| Tbx5 3'     | CCTCTCGAGTCGAAGCTATTTCTGCTCCACTCTG | 71.9 |
antibodies directed toward cardiac troponin T (Abcam), beta myosin heavy chain 7 (MYH7; Sigma), or α-sarcomeric actinin (Sigma). Primary antibodies were bound with fluorescent secondary (647 nm; Alexa Fluor, Invitrogen), and fluorescence was visualized using a Ti-S inverted phase/fluorescent microscope with SPOT cooled 2.0-megapixel digital camera system (Nikon).

Fluorescence Activated Cell Sorting

For fluorescence activated cell sorting analyses, cells were washed with PBS and treated with 0.05% trypsin (Gibco). These cells were then pelleted and permeabilized with 0.1% Saponin for 30 minutes at 4°C, repelleted and suspended in 5% goat serum, and incubated with relevant primary antibodies followed by incubation with a fluorescent secondary antibody (647 nm; Alexa Fluor). Cells were fixed with 1% paraformaldehyde and analyzed for fluorescence using Cell Quest V3.3 software on an FACSCalibur Flow Cytometer (Becton, Dickinson, and Co).28–30

Myocardial Infarction Animal Model

Myocardial infarction was created by coronary ligation, as previously described, in adult male Fisher 344 rats (275 to 300 g; Harlan, Indianapolis, Ind), using protocols approved by the State University of New York, Stony Brook Institutional Animal Care and Use Committee.40,41 Animals were housed, operated on, and cared for in facilities run by the Division of Laboratory Animal Resources at Stony Brook University, which is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International.

Animals were first anesthetized with isoflurane 4% in an induction box, intubated, and placed on a rodent ventilator (Harvard Apparatus) using isoflurane inhalation (3.5%) supplemented with oxygen. Lidocaine (4 mg/kg) was administered intramuscularly. A left thoracotomy was then performed, and the left coronary artery was ligated 1 to 2 mm from its origin with a 7-0 polypropylene suture. This prep consistently produces a gross (pale) anterolateral myocardial infarction with <20% mortality.

At the time of coronary ligation, 5 uniformly distributed 20-μL injections, each containing 2 × 10⁸ particle units (1 × 10⁹ total dose) of Ad VEGF-All6A⁺ or AdNull (n=12/group), were administered around the infarct zone, identified as an area of blanching on the anterolateral wall of the left ventricle, by operators blinded to treatment group. The chest was then sutured closed in a layer-by-layer manner, and the animals were placed in a heated chamber and allowed to recover under supervision. Ketorolac (3 to 5 mg/kg) and buprenorphine (0.05 to 0.1 mg/kg) were administered subcutaneously at the time of closure and every 12 to 24 hours postoperatively as needed, determined by the level of activity displayed by the animals.

A second thoracotomy was performed 3 weeks later, and animals previously receiving AdVEGF-All6A⁺ or AdNull each then underwent administration into the infarct zone of 1 × 10⁵ transducing units of lentivirus (5 uniformly distributed 20-μL injections) encoding Gata4, Mef2c, or Tbx5 coupled to a GFP marker or encoding GFP alone (final n=6/group). Animal were again recovered as described earlier. Euthanasia was later achieved 4 weeks later by deep (4%) isoflurane anesthesia followed by exsanguination, consistent with American Veterinary Medical Association guidelines.

Echocardiography

Echocardiography was performed under light anesthesia with 3% isoflurane using a Veno 770 Imaging System (VisualSonics Inc., Toronto, Ontario, Canada) at 5 different time points: before and 3 days after coronary ligation and AdVEGF-All6A⁺ or AdNull, at the time of GMT or GFP administration 21 days later (baseline), and then 2 weeks and 4 weeks later after baseline (postligation day 35 and day 49, respectively).40,41 Echo images were obtained of the left ventricle in both parasternal long-axis and short-axis views by investigators blinded to treatment group. Left ventricular end-systolic and end-diastolic diameters and left ventricular septal and posterior thickness (in both end-systolic and end-diastolic phases) were measured from M-mode tracings. These imaging data were then analyzed by investigators blinded to treatment group. Change in ejection fraction (EF) was calculated as: (EF at day 49)–(EF at day 21)/EF at day 21).

Histologic Analyses

To obtain cardiac tissue specimens, animals were exsanguinated under deep anesthesia via an incision made in the right atrium. While the heart was still beating, it was perfused with normal saline and fixed with PBS (pH 7.2) containing 4% (w/v) paraformaldehyde via a 25-gauge needle inserted into the left ventricular apex. The heart was then harvested and rinsed with saline to clear the blood. Excised hearts were fixed with 4% paraformaldehyde for 24 hours and then 2% paraformaldehyde for 48 hours at 4°C. The heart was then cut transversally and sectioned with 2 (2- to 3-mm) slices obtained, 1 immediately cephalad and 1 immediately caudal to the transverse centerline of the infarct region, which was readily identifiable by gross inspection. After paraffin embedding of these slices, seven 5-μm-thick sections were obtained at 90-μm intervals.

For analyses of in vivo cellular reprogramming, microscopic slides of every other section obtained as described...
were stained with primary antibodies against beta myosin heavy chain 7 (anti-MYH7, Sigma) and then incubated with secondary IgG antibody. Five microscopic fields per slide (at the center of the infarction zone, in the mid areas between the center of infarction and the border zone [left and right], and in each border zone adjacent to the infarct [left and right]) viewed at ×200 magnification were graded semiquantitatively to determine MYH7+ cell density. Density grading assessed by an investigator blinded to treatment group were defined as follows: grade I: <25% of selected microscopic field demonstrating MYH7+ cells; grade II: 25% to 50% of selected microscopic field demonstrating MYH7+ cells; grade III: 50% to 75% of selected microscopic field demonstrating MYH7+ cells; and grade IV: >75% of selected microscopic field demonstrating MYH7+ cells (Figure 1). These observations are reported as the percentage of fields per animal demonstrating a given density grade and the mean of these percentages per group for all animals with at least 10 fields analyzable within an infarct zone.

To assess the extent of fibrosis, 22 sections per animal (at a 120-μm interval between each section) obtained as described earlier were stained with Masson’s trichrome. The fibrotic area (blue) and the nonfibrotic region (red) were outlined using Adobe Photoshop CS5 software, and then quantified with MATLAB and Simulink software (MathWorks, Inc). The total area of fibrosis was calculated as: (total of blue pixels from all sections/total of blue plus red pixels from all sections).

For myofibroblast identification, 2 sections per animal demonstrating the greatest cross-sectional area of fibrosis, as determined by trichrome staining, were stained for α-smooth muscle actin (α-SMA; Anti-Actin-Smooth Muscle, Spring Bioscience). α-SMA–positive cells in these sections exclusive of those found in vascular structures or endocardium were counted at ×200 magnification.

For vascularization studies, the number of vessels per microscopic field was determined from the sections stained as described with α-SMA or with factor VIII (anti–factor VIII–related antigen, Ventana) and counted at ×200 or ×400, respectively.

Statistical Analysis

Statistical analysis was performed with SAS version 9.2. The data are presented as mean±SEM. The normality of the data was examined with Shapiro–Wilk. When there was a normal distribution, an ANOVA was performed to detect statistical significances between multiple groups. When the ANOVA showed significance, a Student t test was performed with a post hoc Holm–Bonferroni correction. When there was not a normal distribution, a Kruskal–Wallis test was performed. When the test was significant, the Wilcoxon rank test was performed with a post hoc Holm–Bonferroni correction. For categorical variables, a Fisher exact test was performed. Values of P<0.05 were considered statistically significant.

Results

In Vitro iCM Generation

The competency of each of the GMT lentivirus vectors was confirmed by in vitro cell infection assays, which demonstrated expression of all 3 of the reprogramming transcription factors (Figure 2). Confirmation of the ability of these transcription factors to induce iCM transdifferentiation was obtained by immunofluorescence staining of rat dermal fibroblasts after GMT lentiviral transduction. In these studies, cells exposed to GMT vectors expressed cardiomyocyte-specific markers including cardiac troponin T, α-sarcomeric actin in, and MYH7, while uninfected cells and fibroblasts exposed only to a GFP control vector failed to express these markers (Figure 3A). On fluorescence activated cell sorting quantification, GMT infection demonstrated evidence of cardiomyocyte marker expression by ∼7% of infected fibroblasts (Figure 3B through 3F).
Vascularization of Infarcted Myocardium

Vascularization of the infarcted region as assessed by α-SMA staining was significantly greater in AdVEGF-All6A−/−-treated animals than in animals receiving an AdNull control vector: 5.5±0.9 vs 3.3±0.4, respectively; P<0.05 (Figure 4). A similar, approximate 2-fold increase in vessels stained with factor VIII was noted in animals receiving AdVEGF-All6A−/− alone vs those receiving AdNull alone (14.1±2.1 vs 7.3±1.4, P<0.05).

Histologic Assessment of Postinfarct Ventricles

To assess the efficacy of GMT administration with or without VEGF pretreatment in vivo, a series of histologic analyses were performed on sections of the heart obtained 4 weeks after GMT/GFP delivery (7 weeks after coronary ligation and AdVEGF-All6A−/−/AdNull administration). These studies demonstrated a greater density of cells staining for the cardiomyocyte marker MYH7 in the infarct zone in GMT-treated animals compared with control animals (Figure 5A through 5D). Typically, GMT-treated animals demonstrated relatively large islands of MYH7+ cells compared with sparse foci of MYH7+ in control animals.

Using a grade I to IV scale to semiquantitatively assess MYH7 cell density, GMT-treated animals demonstrated grade III/IV MYH7 cell density in the infarct zone in a greater percentage of microscopic fields than did GFP control animals, in both the infarct zone and border zones (Table 2). The percentage of microscopic fields demonstrating grade III/IV MYH7 cell density was significantly greater in GMT-treated animals compared with GFP-treated control animals (36±8% vs 7±4%, P<0.01) in the infarct zone and in the border zones adjacent to infarct zones (65±10% vs 23±9%, P<0.01). Notably, none of the sections demonstrated grade IV MYH7 cell density in the infarct zone in the GFP control groups (Table 2). Administration of AdVEGF-All6A−/− did not significantly alter MYH7 cell density (Figure 5E).

The extent of fibrosis in these sections, as detected by trichrome staining, was also significantly reduced in GMT-treated animals compared with those receiving GFP, regardless of VEGF administration (Figure 6A). The cross-sectional area of fibrosis in these groups, as a percentage of total left ventricular myocardial area in sections analyzed, was 12±2% vs 24±3% (P<0.01). No difference in the extent of fibrosis was detected in animals treated with AdVEGF-All6A− without GMT compared with AdNull/GFP controls (Figure 6B). Also, AdVEGF-All6A− administration did not further reduce the extent of fibrosis compared with animals treated with GMT without VEGF.

Consistent with the reduction in fibrosis detected in GMT-treated animals, there was approximately a 4-fold decrease in the number of myofibroblasts observed in GMT-treated animals compared with control animals, regardless of VEGF administration (Figure 7).

Improvement in Ventricular Function After GMT and VEGF Administration

Echocardiography was performed to assess the functional implications of the outcomes noted above. Echo analyses performed before and immediately after coronary ligation demonstrated that EF was reduced by ≈30% from baseline values (Figure 8A). This decrease in cardiac function persisted 3 weeks later, at the time of GMT or GFP lentivirus administration.

As detailed in Table 3, mean EF 4 weeks after GMT or GFP administration was greatest for animals receiving GMT administration with AdVEGF-All6A− pretreatment (AdVEGF-All6A−/GMT), being significantly greater than animals receiving either AdVEGF-All6A− without GMT (AdVEGF-All6A−/GFP; P<0.05) or both control vectors (AdNull/GFP; P<0.05). Similar observations were made for differences between groups in fractional shortening (Table 4). When grouped together regardless of prior AdVEGF administration, GMT-treated animals demonstrated significantly greater mean EF compared with similarly combined GFP control animals, both at 2 weeks and at 4 weeks after lentivirus administration.
Figure 3. iCM generation in vitro. Primary rat dermal fibroblast (RDF) cells were cultured and infected with GMT or a GFP control lentivirus as described in Methods. Fourteen days after infection, cells were fixed and stained for specified cardiomyocyte markers. A. Immunofluorescence studies. First column represents 4',6-diamidino-2-phenylindole (DAPI) staining to identify cell nuclei. Second column represents GFP fluorescence to identify cells infected by at least one of the lentivirus vectors. Third column represents red staining of relevant cardiomyocyte markers (first row: cardiac troponin T [cTnT]; second row: myosin heavy chain 7 [MYH7]; third row: α-sarcomeric actinin). Fourth column depicts merge of previous 3 images. Note coincidence of these respective markers and binucleated cells typical of cardiomyocyte, and that GFP (-) cells also fail to express markers. Uninfected RDFs did not express either marker (not shown). All photomicrographs were taken at x400 magnification (bar=50 μm). B through F, FACS analysis. Depicted are FACS plots for cTnT staining after: (B) RDFs infected with GMT, demonstrating 7% expression of cTnT in GFP+ cells, (C) RDFs infected with GFP control lentivirus, (D) uninfected RDFs, (E) primary cardiomyocyte control, and (F) RDFs infected with GMT, with use of secondary antibody only. Graphs show a minimum of 5000 events. iCM indicates induced cardiomyocytes; GMT, Gata4, Mef 2c, and Tbx5; FACS, fluorescence activated cell sorting.
(2 weeks: 63±2% vs 52±2%, P<0.01; 4 weeks: 60±2% vs 49±2%, P<0.001). In comparison, no difference in EF was seen after AdVEGF-All6A+ administration alone (without GMT) vs animals receiving control vectors.

The change in EF from the time of the lentivirus administration baseline to the time of follow-up echo 4 weeks later (Figure 8B, top) was also greater in the GMT vs GFP groups (12±3% vs -7±3%, P<0.01). Eight (73%) GFP-treated animals but none of the GMT-treated animals demonstrated decreased EF during this interval (P<0.01). Moreover, as depicted in Figure 8B (bottom), the improvement in EF observed in the AdVEGF-All6A+/GFP group was 4 times greater than that observed for the AdNull/GMT group (17±2% vs 4±1%, P<0.05) and was significantly greater (P=0.008) than the change in EF observed after administration of VEGF alone (AdVEGF-All6A+/GFP).

Interestingly, systolic wall thickening of the (remote, noninjected) left ventricular posterior wall also trended toward greater values in the GMT/VEGF group compared with animals receiving GMT without VEGF and compared with GFP/AdNull controls (Figure 8C).

Discussion

The current study uses adenovirus-mediated VEGF administration into infarcted myocardium to enhance the improvements in EF observed as early as 14 days after administration of the cellular reprogramming transcription factors Gata4, Mef2c, and Tbx5 alone. In addition to the novel incorporation of angiogenic preconditioning of the infarct milieu in this in situ myocardial regeneration strategy, the current work now also extends prior investigations by using a lentivirus vector to transfer GMT reprogramming factors in a second animal model, beyond the mouse model used to date. These current data stand in contradistinction to the recent work of other investigators, reported by Chen et al, suggesting that cellular reprogramming mediated by GMT strategy was ineffectual. Importantly, in situ cellular reprogramming offers the possibility of avoiding the challenges of current exogenous stem cell administration strategies, including the logistic barriers of cell procurement, expansion, and/or efficient delivery of such cells into a host myocardium. On the other hand, we now also demonstrate that angiogenic preconditioning of the infarcted myocardium enhances the efficacy of this strategy, extending prior observations with stem cell implants to this in situ strategy.

The presumptive origin of improvements in postinfarct ventricular function in the current and prior cellular reprogramming studies is the generation of functional iCMs in areas of myocardial scar, as suggested by other investigators, and the enhancement of the survival and/or function of these "reprogrammed" myocytes by scar prevascularization. Interestingly though, our observations reinforce prior investigators’ (previously undiscovered) observations of improvements in EF and decreases in fibrosis after cellular reprogramming that seem to far exceed what would be expected solely on the basis of the relatively inefficient generation of iCMs from
substrate cells. More specifically, in comparison to a rate of transdifferentiating infarct fibroblasts into iCMs in vivo in the range of 1% to 20%, reductions in fibrosis and improvements in EF ranging up to 50% in the current and prior studies suggest alternative or additional mechanisms might be responsible for these outcomes.

Several possible mechanisms, including ones related and unrelated to iCM generation, might explain these apparently disparate outcomes. First, it is theoretically possible that inconsistent coronary ligation technique and/or extent of infarction induced by ligation may be accountable for the differences in fibrosis/infarction observed in treated vs untreated animals. The development of significantly different treatment outcomes in the current study from baseline values that were not significantly different between groups argues against this possibility, as do the statistically significant improvements in function demonstrated between groups in the current study when using the baseline function of each

Figure 5. Cardiomyocyte density in infarct zones. Cardiomyocyte-specific marker MYH7 staining of the infarct and border zones of sections of myocardium harvested 7 weeks after coronary ligation and administration of AdVEGF-All6A⁺ or the control vector AdNull (4 weeks after the administration of lentivirus encoding GMT or a GFP control). A through D, Photomicrographs of representative sections of infarct zones from animals treated with AdVEGF-All6A⁺/GMT (top row) or AdNull/GFP (bottom row) at ×100 (left) and ×200 (right) magnification, respectively. Bars represent 100 μm. E, Depiction of MYH7 cell density as a percent of total sections analyzed (n=6/group). Grade I/II indicates than <50% of the examined microscopic fields were occupied by MYH7⁺ cells; grade III/IV indicates than >50% of the examined microscopic fields were occupied by MYH7⁺ cells (see Methods for definitions and Figure 1 for microscopic fields representative of each density grade). MYH7 indicates myosin heavy chain 7; VEGF, vascular endothelial growth factor; GMT, Gata4, Mef2c, and Tbx5; GFP, green fluorescent protein.
animal as its own control. In the context of 2 previous studies that yielded similar outcomes, the larger sample size of these pooled data would seem to make it even less likely that these observations are attributable to an artifact due to coronary ligature technique.

Assuming then that the observed differences in cardiac function are not artifactual, several causal mechanisms must be considered. The first simply implicates the generation of functionally competent, contractile iCMs that individually contribute to the restoration of global cardiac function. The significant increases in MYH7+ (cardiomyocyte) cell density in GMT-treated vs control animals that we have observed in both the infarct and border zones, similar to the previous observations of Qian et al and Song et al, are supportive of this mechanism. Alternatively, the generation of iCMs in thinned zones of infarction might improve wall stresses and thereby decrease global myocardial workloads, as supported by our observations of the improved systolic function of remote left ventricular wall segments in treated animals and as previously postulated to be a mechanism of action underlying the efficacy of stem cell implant therapies.

The dramatic decreases in fibrosis seen in treated animals in this and prior studies that appear to far exceed increases in the number of newly generated iCMs suggest that these observed reductions in fibrosis might also contribute to the significant improvements in EF observed in treated animals. Based on our preliminary data, it is conceivable that a paracrine effect of a relatively limited number of iCMs might underlie this reduction in fibrosis, due to the expression by iCMs of chemokines such as basic fibroblast growth factor and tissue inhibitor of matrix metalloproteinase–2 that have been reported to limit or reduce fibrosis.

Table 2. MYH7+ Cell Density

| Infarction area          | Grade I  | Grade II | Grade III | Grade IV |
|--------------------------|----------|----------|-----------|----------|
| AdVEGF-All6A+/GMT        | 12±5     | 44±8     | 30±7      | 14±5     |
| AdNull/GMT               | 29±13    | 41±8     | 22±7      | 8±5      |
| AdVEGF-All6A+/GFP        | 61±14    | 34±13    | 5±3       | 0        |
| AdNull/GFP               | 50±14    | 40±10    | 10±6      | 0        |
| Border zone area         |          |          |           |          |
| AdVEGF-All6A+/GMT        | 4±3      | 29±9     | 48±10     | 19±7     |
| AdNull/GMT               | 14±10    | 24±7     | 38±9      | 25±10    |
| AdVEGF-All6A+/GFP        | 30±14    | 48±11    | 21±12     | 1±1      |
| AdNull/GFP               | 43±13    | 32±7     | 22±10     | 3±2      |

MYH7 indicates myosin heavy chain 7; VEGF, vascular endothelial growth factor; GMT, Gata4, Mef2c, and Tbx5.

*Percentage of microscopic fields analyzed demonstrating density grade (n=6 animals per treatment group).

†Grade I: <25% of microscopic field containing MYH7+ cells; grade II: 25% to 50% of microscopic field containing MYH7+ cells; grade III: 50% to 75% of microscopic field containing MYH7+ cells; grade IV: >75% of microscopic field containing MYH7+ cells. All measurements at x200.

Figure 6. Extent of left ventricular wall fibrosis. The percent of left ventricular myocardial wall area demonstrating fibrosis as determined by trichrome staining of sections of myocardial tissue harvested 7 weeks after coronary ligation and administration of AdVEGF-All6A+ or the control vector AdNull (4 weeks after the administration of lentivirus encoding GMT or a GFP control) animals is depicted. A, Extent of fibrosis in animals receiving GMT versus GFP control vectors (n=12); *P<0.01. B, Extent of fibrosis for the 4 treatment groups (n=6/group); *P<0.05. GFP indicates green fluorescent protein; GMT, Gata4, Mef2c, and Tbx5; VEGF, vascular endothelial growth factor.
Alternatively, it is conceivable that administration of cellular reprogramming and/or VEGF transgenes diverts resident/scar fibroblasts away from their normal postinfarct differentiation into myofibroblasts, known to produce fibrosis via expression of collagen and other extracellular matrix components, and toward a more benign fate as iCMs.43–50

The 4-fold reduction of myofibroblast populations we observed in GMT-treated animals vs controls, consistent with a similar trend in reduced extent of fibrosis, supports this supposition. Theoretically, alternative processes such as myofibroblast apoptosis and/or repressed function (ie, decreased extracellular matrix component expression) could also play a role in such mechanisms.43–50

The use in the current study of lentivirus and adenovirus vectors that infect dividing and nondividing cells (including cardiomyocytes) raises the possibility also of GMT/VEGF effects on resident cardiomyocytes in addition to the targeting of fibroblasts in several prior studies.30–34 Some evidence in the literature suggests that such effects might include changes in cardiomyocyte structure, function, or stability/resistance to ischemia (ie, cardiac “super cells”).43–50 GMT and/or VEGF when administered via these vectors might influence the differentiation of other nonproliferating cells, such as resident cardiac progenitor cells, fibroblasts, or endocardial cells toward a cardiomyocyte fate and/or away from a myofibroblast phenotype.

We and others have previously demonstrated that scar vascularization is important to support the survival and function of stem cell implants, and we have delayed GMT administration for 21 days after AdVEGF-All6A+ in accordance with our prior studies demonstrating a plateau in neovascularization beginning 3 weeks after the administration of VEGF.40–42 Preliminary cell survival studies that we have conducted likewise suggest that similar considerations would apply to observation of increased neovascularization providing the nutrient perfusion needed to support the conversion of low metabolic fibroblasts into high metabolic iCMs.

The importance of scar prevascularization to the presently described in situ cellular reprogramming strategy is supported by our observation of the ability of AdVEGF to induce scar vascularization in the setting of the acute myocardial infarction model used in the current study, together with our observation of significant improvements in EF when VEGF was administered as a supplement to GMT compared with the administration of GMT without VEGF. In the context of the lag in neovascularization induced by VEGF relative to the more rapid time course of myocardial infarction, and our observations of an equivalent extent of fibrosis in animals treated with vs without VEGF, the (comparatively limited) improvement in EF observed after VEGF administration (without GMT) is potentially attributable to the antiapoptotic properties of VEGF, as well as its angiogenic properties in promoting the viability and/or function of border zone cells.43–50

Study Limitations

One significant limitation of the current study is that our use of a rat model as opposed to a mouse model precludes...
our readily accessing transgenic techniques to facilitate “cell of origin” studies. The limited visualization of GFP markers that we experienced at the extended, 7-week end point of these studies further impaired these investigations. Given prior studies confirming scar fibroblasts as the source of iCMs in vivo, we believe that the advance of this work to a larger animal model and a second species outweighs the disadvantages of not being able to generate these otherwise duplicative data. This limitation is also mitigated by our demonstration of differences between groups in cardiomyocyte and myofibroblast marker positive cells, which has provided new insights into potential mechanisms of actions.

A second limitation of this and prior cellular reprogramming studies is the relatively inefficient transdifferentiation rate of fibroblasts into iCMs. Although Song et al appear to have made progress in addressing this challenge by their addition of a fourth reprogramming gene, HAND2, to their treatment “cocktail,” the need to “hit” target cells with 4 different gene transfer vectors remains a limitation of current vector strategy. Alternative “triple transgene” or other vector constructs and/or microRNA strategies as...
Table 3. Ejection Fraction Group Means as Assessed by Echocardiography*

| Group                  | Time, d  |
|------------------------|----------|
|                        | 0 | 3 | 21 | 35 | 49 |
| AdVEGF-All6A+/GMT      | 75±2 | 55±3 | 54±2 | 65±2 | 63±2 | 56±2 |
| AdNull/GMT             | 75±1 | 56±3 | 53±2 | 61±3 | 56±2 | 56±2 |
| AdVEGF-All6A+/GFP      | 76±1 | 51±3 | 51±2 | 53±4 | 51±2 | 58±2 |
| AdNull/GFP             | 74±1 | 51±2 | 53±3 | 52±3 | 48±2 | 58±2 |

*All data expressed as a percentage ejection fraction (n=6 animals per treatment group). VEGF indicates vascular endothelial growth factor; GMT, Gata4, Mef2c, and Tbx5; MYH7, myosin heavy chain 7. 
1Day 0 represents time of coronary ligation and AdVEGF-All6A or AdNull administration; day 21 represents time of administration of lentivirus encoding GMT or GFP.
2AdVEGF-All6A+/GMT versus AdNull/GMT at day 49: P<0.05.
3AdVEGF-All6A+/GMT versus AdVEGF-All6A+/GFP at day 49: P<0.05.
4AdVEGF-All6A+/GMT versus AdNull/GMT at day 49: P=0.08.
5AdVEGF-All6A+/GFP versus AdNull/GFP: P<0.08.

Table 4. Ventricular Functional Metrics as Assessed by Echocardiography*

| Parameter                  | Time, d  |
|----------------------------|----------|
|                            | 0 | 3 | 21 | 35 | 49 |
| End-diastolic volume       |       |
| AdVEGF-All6A+/GMT          | 217±7 | 181±13 | 215±17 | 222±21 | 234±25 |
| AdNull/GMT                 | 206±8 | 147±18 | 239±12 | 208±16 | 231±23 |
| AdVEGF-All6A+/GFP          | 192±11 | 197±11 | 302±30 | 240±32 | 280±32 |
| AdNull/GFP                 | 207±13 | 193±19 | 262±17 | 265±32 | 252±26 |
| End-systolic volume        |       |
| AdVEGF-All6A+/GMT          | 54±5 | 80±7 | 99±10 | 80±11 | 84±7 |
| AdNull/GMT                 | 51±2 | 65±5 | 112±10 | 81±10 | 105±14 |
| AdVEGF-All6A+/GFP          | 47±3 | 97±8 | 148±17 | 117±23 | 139±20 |
| AdNull/GFP                 | 54±4 | 95±11 | 123±11 | 131±23 | 134±18 |
| Fractional shortening      |       |
| AdVEGF-All6A+/GMT          | 45±2 | 30±2 | 29±1 | 36±2 | 35±1.5 |
| AdNull/GMT                 | 45±1 | 29±2 | 28±1 | 34±2 | 30±1.5 |
| AdVEGF-All6A+/GFP          | 46±1 | 27±2 | 27±1 | 28±2 | 27±1 |
| AdNull/GFP                 | 44±1 | 27±1 | 28±2 | 27±2 | 25±1 |

*All data expressed as a percentage ejection fraction (n=6 animals per treatment group). VEGF indicates vascular endothelial growth factor; GMT, Gata4, Mef2c, and Tbx5; MYH7, myosin heavy chain 7.
1Day 0 represents time of coronary ligation and AdVEGF-All6A or AdNull administration; day 21 represents time of administration of lentivirus encoding GMT or GFP.
2No significant difference between groups at any time interval.
3AdVEGF-All6A+/GMT versus AdNull/GMT: P<0.08.
4AdVEGF-All6A+/GMT versus AdVEGF-All6A+/GFP: P<0.01.
5AdVEGF-All6A+/GMT versus AdNull/GFP: P<0.0001.
6AdNull/GMT versus AdNull/GFP: P<0.07.

Finally, it is conceivable that delayed administration of either the adenovirus or lentivirus vectors might likewise yield greater effect if this administration was delayed to allow amelioration of the immediate postinfarct inflammatory milieu. Unfortunately, this strategy would be a prohibitive technical challenge in the current small animal model as it would involve 3 operations. Testing of this hypothesis in additional studies at extended time points to ensure that transdifferentiation remains stable is planned in a larger animal model now that these “proof of principle” data have been established.
Conclusions
In the context of these limitations, the present study advances prior cellular reprogramming investigations by now incorporating angiogenic pretreatment of the infarcted myocardium as a means of enhancing a new, potentially clinically meaningful strategy to improve the function of postinfarct myocardium. Whereas the mechanisms underlying these outcomes are still not fully elucidated, it would appear that iCM generation from scar fibroblasts in situ likely contributes to this process.

Acknowledgments
We thank Jamie Romeiser, MPH, for her help with statistical analysis.

Sources of Funding
This study was supported in part by a grant from James and Lisa Cohen to Dr Rosengart and Dr Crystal, and by National Heart, Lung, and Blood Institute grant 5R01HL0855095-05 to Dr Rosengart.

Disclosures
None.

References
1. AHA statistical update heart disease and stroke statistics—2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:480–486.
2. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Keck BM, Hertz MI. Registry of adult heart transplant report. J Heart Lung Transplant. 2002;21:794–803.
3. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG, Naka Y, Mancini D, Miller LW. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007;116:497–505.
4. Anyanwu A, Treasure T. Prognosis after heart transplantation: transplants alone cannot be the solution for end stage heart failure. Br Med J. 2003;326:509–510.
5. Leor J, Patterson M, Quinones MJ, Kedes LH, Kloner RA. Transplantation of fetal myocellular tissue into the infarcted myocardium of rat: a potential method for repair of infarcted myocardium? Circulation. 1996;94: II332–II336.
6. Taylor DA, Atkins BZ, Hunspreuga P, Jones TR, Reedy MC, Hutcheson KA, Glowar DD, Kraus WE. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4:929–933.
7. Tomita S, Li R-K, Weisel RD, Mickle DAG, Kim EJ, sakai T, Jia ZQ. Autologous regeneration of bone marrow cells improves damaged heart function. Circulation. 1999;100:II247–II256.
8. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Picket J, McKay R, Natal-Girard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;414:701–704.
9. Scorsin M, Hagege A, Vilquin JT, Fiszman M, Marotte F, Samuel JL, Rappaport L, Schwartz K, Menasche P. Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg. 2000;119:1169–1175.
10. Hare JM, Chaparro SV. Cardiac regeneration and stem cell therapy. Curr Opin Organ Transplant. 2008;13:536–542.
11. Rosenzweig A. Cardiac cell therapy—mixed results from mixed cells. N Engl J Med. 2006;355:1274–1277.
12. Murry CE, Reinecke H, Pabon LM. Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol. 2006;47:1777–1785.
13. Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol. 2011;50:258–265.
14. Min JY, Yang Y, Converso KL, Liu L, Huang Q, Morgan JP, Xiao YF. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J Appl Physiol. 2002;92:288–296.
15. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblastsof defined factors. Cell. 2007;131:861–872.
16. Yu J, Vodyanik MA, Smuga-Otto K, Anosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–1920.
17. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313–317.
18. Xua D, Alipioza Z, Finka LM, Adcock DM, Yang J, Warda DC, Ma Y. Phenotypic correction of murine hemophilia A using a iPSC cell-based therapy. Proc Natl Acad Sci USA. 2009;106:808–813.
19. Gai H, Leung ELH, Costantino PD, Aguila JR, Nguyen DM, Fink LM, Ward DC, Ma Y. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biol Int. 2009;33:1184–1193.
20. Mauritz C, Schwanke K, Reppel M, Neef S, Hescheler J, Hasenfuss G, Martin U, Maier LS, Nguemo F, Menke S, Haustein M. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation. 2008;118:507–517.
21. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation. 2009;120:408–416.
22. Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008;118:498–506.
23. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30–e41.
24. Okita K, Nagata N, Yamanaka S. Immunogenicity of induced pluripotent stem cells. Circ Res. 2011;109:720–721.
25. Apostolous E, Hochledinger K. iPS cells under attack. Nature. 2011;474:165.
26. Mummery C. Induced pluripotent stem cells—a cautionary note. N Engl J Med. 2011;364:2160.
27. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212–214.
28. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Brunee BG, Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010;142:375–386.
29. Efe JA, Hilcove S, Kim J, Zhou H, Ouyang K, Wang G, Chen J, Ding S. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol. 2011;13:215–222.
30. Qian L, Huang Y, Spencer CL, Foley A, Vedantham V, Liu L, Conway SJ, Fu J, Srivastava D. In vivo reprogramming of murine cardiac fibroblasts into functional cardiomyocytes. Nature. 2012;485:593–598. doi:10.1038/nature11044.
31. Passier R, Mummery C. Getting to the heart of the matter: direct reprogramming to cardiomyocytes. Cell Stem Cell. 2010;7:139–141.
32. Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD, Neilson EG, Hill JA, Bassel-Duby R, Olson E. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature. 2012;485:599–604. doi:10.1038/nature11339.
33. Srivastava D, Ieda M. Critical factors for cardiac reprogramming. Circ Res. 2012;111:5–8.
34. Jayawardena TM, Eggenzaverov B, Finch EA, Zhang L, Payne JA, Pandya K, Zhang Z, Rosenberg P, Mikosuzo M, Dzau VJ. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res. 2012;110:1465–1473.
35. Prozte S, Khattak S, Poulet C, Lindemann D, Tanaka EM, Ravens U. A new approach to transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells. J Mol Cell Cardiol. 2012;53:323–332. doi:10.1016/j.mcc.2012.04.010.
VEGF Enhances Cellular Reprogramming

Mathison et al

36. Chen CJX, Krane M, Deutsch MA, Wang L, Rav-Acha M, Greigoire S, Engels MC, Rajarajan K, Karrar R, Abel ED, Wu JC, Milan D, Wu SM. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ Res. 2012;111:50–55. doi:10.1161/CIRCRESAHA.112.270264

37. Zhang M, Method D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol. 2001;33:907–921.

38. Reinecke H, Zhang M, Bartosek T, Murry CE. Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Circulation. 1999;100:193–202.

39. Laflamme MA, Chen KY, Naumova AV, Muskheili V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O’Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Murr CE. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25:1015–1024.

40. Retuerto MA, Schalch P, Patejunas G, Carbray J, Liu N, Esser K, Crystal RG, Rosengart TK. Angiogenic pre-treatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation. J Thorac Cardiovasc Surg. 2004;127:1041–1049.

41. Retuerto MA, Beckmann JT, Carbray J, Patejunas G, Sarateanu S, Kane B, McPherson D, Rosengart TK. Angiogenic pre-treatment enhances myocardial function following cellular cardiomyoplasty with skeletal myoblasts. J Thorac Cardiovasc Surg. 2007;133:478–484.

42. Amano H, Hackett NR, Kaner RJ, Whitlock P, Rosengart TK, Crystal RG. Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms and safety of angiogenic gene therapy. Mol Ther. 2002;12:716–724.

43. Daskalopoulos EP, Janssen BJA, Blanksteijn WM. Myofibroblasts in the infarct area: concepts and challenges. Microsc Microanal. 2012;18:35–49.

44. Fedak PWM, Liping B, Turnbull J, Ngu J, Narine K, Duff H. Cell therapy limits myofibroblast differentiation and structural cardiac remodeling. Circ Heart Fail. 2012;5:349–356.

45. Van den Borne SWM, Diez JW, Blanksteijn M, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7:30–37.

46. Chen Y, Amende I, Hampton TG, Yang Y, Ke O, Min JY, Xiao YF, Morgan JP. Vascular endothelial growth factor promotes cardiomyocyte differentiation of embryonic stem cells. Am J Physiol Heart Circ Physiol. 2006;291:H1653–H1658.

47. Yang Y, Min J-Y, Rana JS, Ke O, Cai J, Chen Y, Morgan JP, Xiao Y-F. VEGF enhances functional improvement of postinfarcted hearts by transplantation of ESC-differentiated cells. J Appl Physiol. 2002;93:1140–1151.

48. Zhang J, Ding L, Zhao Y, Sun W, Chen B, Hang Lin H, Wang X, Zhang L, Xu B, Dai J. Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction. Circulation. 2009;119:1776–1784.

49. Song YH, Gehmert S, Sadat S, Pinkernell K, Bai X, Matthias N, Alt E. VEGF is critical for spontaneous differentiation of stem cells into cardiomyocytes. Biochem Biophys Res Commun. 2007;354:999–1003.

50. Claes F, Vandevelde W, Moons L, Tjwa M. Another angiogenesis-independent role for VEGF: SDF1-dependent cardiac repair via cardiac stem cells. Cardiovasc Res. 2011;91:369–376.

51. Yamaguchi T, Hamaoka S, Kamiya A, Okabe M, Kawarai M, Wakiyama Y, Umino A, Hayama T, Sato H, Lee YS, Kato-Itoh M, Masaki H, Kobayashi T, Yamazaki S, Nakauchi H. Development of an all-in-one inducible lentiviral vector for gene specific analysis of reprogramming. PLoS ONE. 2012;7:e41007. doi:10.1371/journal.pone.0041007.

52. Kohe Inagawa K, Miyamoto K, Yamakawa H, Muraoka N, Sadahiro T, Umei T, Wada R, Katsumata Y, Kaneda R, Nakade K, Kurihara C, Obata Y, Miyake K, Fukuda K, Ieda M. Induction of cardiomyocyte-like cells in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. Circ Res. 2012;111:1147–1156.